Ruxolitinib    (DrugBank: Ruxolitinib)

1 disease
IDDisease name (Link within this page)Number of trials
228Bronchiolitis obliterans1

228. Bronchiolitis obliterans    [ 92 clinical trials,   125 drugs,   (DrugBank: 34 drugs),   33 drug target genes,   152 drug target pathways]
Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 92 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03674047
(ClinicalTrials.gov)
April 19, 201914/9/2018Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)Other CancerDrug: ruxolitinibMassachusetts General HospitalIncyte CorporationRecruiting18 Years75 YearsAll50Phase 2United States